Tuberculosis Clinical Trial
Official title:
Clinical Analysis of the Patients With Cavitary Pulmonary Tuberculosis and Endobronchial Tuberculosis in the Private-Public Mix Project for Tuberculosis, Ulsan University Hospital Cohort (PPM-UUH Cohort)
Verified date | June 2019 |
Source | University of Ulsan |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational [Patient Registry] |
This study is a retrospective cohort study. The purpose of this study is to investigate clinical features of the patients with the cavitary pulmonary tuberculosis (TB) and endobronchial TB from the patients who have been registered in this hospital for treatment and follow-up, as part of the "PPM Project (Private-Public Mix project) for Korean National Tuberculosis Control" introduced in Korea since 2007.
Status | Completed |
Enrollment | 500 |
Est. completion date | June 30, 2018 |
Est. primary completion date | June 30, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
A. Cavitary Pulmonary TB Group Inclusion Criteria: 1. Aged 18 years and older 2. The patient who has the cavitary pulmonary TB Exclusion Criteria: 1. Age < 18 years 2. Any Malignant patient 3. Patients with bacterial or viral or fungal pneumonia based on the judgment of the attending physician 4. Patients who had a history of any pulmonary cystic lesion such as infected bulla, bullous emphysema 5. Patients who were diagnosed with pulmonary fungal infection or previous its history or any documented culture of the fungus from a bronchial sample including sputum 6. Patients who were diagnosed with bronchiectasis 7. Patients who were diagnosed with NTM-PD (non-tuberculous mycobacterial pulmonary disease) or any documented culture of NTM from a bronchial sample including sputum 8. Patients who were diagnosed with connective tissue disease such as Wegener's granulomatosis, SLE 9. Patients who were diagnosed with TB destroyed lung 10. Patients who were diagnosed with congenital lung disease such as Congenital Cystic Adenomatoid Malformation (CCAM), pulmonary sequestration 11. Patients who were diagnosed with interstitial lung disease such as Lymphangioleiomyomatosis (LAM), idiopathic pulmonary fibrosis (IPF) 12. Patients who were diagnosed with culture-negative pulmonary TB 13. Patients who did not take anti-TB medication more than twice a week on average 14. Patients who were diagnosed with sarcoidosis 15. Patients who were diagnosed with paragonimiasis 16. Patients who were diagnosed with pulmonary thromboembolism due to excluding pulmonary infarction 17. The patient who did not consent 18. Patients who were diagnosed with MDR/XDR TB through AFB culture B. Endobronchial TB Group Inclusion Criteria: 1. Aged 18 years and older 2. The patient who has the endobronchial TB through bronchoscopy Exclusion Criteria: 1. Age < 18 years 2. Patient who was not consented |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Ulsan University Hospital, 877 Bangeojin Sunwhando-ro | Ulsan |
Lead Sponsor | Collaborator |
---|---|
University of Ulsan | Ulsan University Hospital |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | TLSD | Treatment of anti-TB medication to Last Smear positive Duration | at baseline | |
Primary | TLCD | Treatment of anti-TB medication to Last Culture positive Duration | at baseline | |
Primary | ACSD | AFB Culture-Smear positive Dissociation | at baseline | |
Primary | TCV/RLV | TCV/RLV (Total Cavity[ies] Volume/Total Lung Volume) on enhance CT | at baseline | |
Primary | TTV/RLV | TTV/RLV (Total TB lesion Volume/Total Lung Volume) on enhance CT | at baseline | |
Secondary | Radiological measure for Tb lesions including cavity size, number | analysis by BioView Duet Workstation (BioView Ltd, Rehovot, Israel) [cavitary pulmonary TB] | at baseline | |
Secondary | Admission Duration | The patients' Hospital admission duration [cavitary pulmonary TB and endobronchial TB] | at baseline | |
Secondary | Isolation Duration | The patients' isolation duration during hospital admission [cavitary pulmonary TB and endobronchial TB] | at baseline | |
Secondary | Hemoptysis /Bronchial artery embolization (BAE) | The patients' history of Hemoptysis /Bronchial artery embolization (BAE) [cavitary pulmonary TB and endobronchial TB] | at baseline | |
Secondary | TB PCR, XPERT | The patients' result of TB PCR, XPERT [cavitary pulmonary TB and endobronchial TB] | at baseline |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05738681 -
Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial
|
Phase 2/Phase 3 | |
Recruiting |
NCT05526885 -
Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa
|
N/A | |
Completed |
NCT04369326 -
Community Initiated Preventive Therapy for TB
|
N/A | |
Recruiting |
NCT04568967 -
TB-CAPT EXULTANT - HIV
|
N/A | |
Completed |
NCT02337270 -
Phase 1 Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol
|
Phase 1 | |
Not yet recruiting |
NCT06253715 -
Shortened Regimen for Drug-susceptible TB in Children
|
Phase 3 | |
Recruiting |
NCT04271397 -
Immunological Biomarkers in Tuberculosis Management
|
N/A | |
Withdrawn |
NCT03639038 -
Tuberculosis Diagnosis by Flow Cytometry
|
||
Completed |
NCT03199313 -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid
|
Phase 1 | |
Recruiting |
NCT04975178 -
Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa
|
Phase 3 | |
Completed |
NCT04463680 -
Rifampin and the Contraceptive Implant
|
Phase 4 | |
Completed |
NCT03973970 -
Assessing the Ability of the T-SPOT®.TB Test (IQ)
|
||
Recruiting |
NCT04230395 -
Alcohol Reduction Among People With TB and HIV in India
|
N/A | |
Completed |
NCT04874948 -
Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment
|
Phase 1 | |
Active, not recruiting |
NCT02906007 -
Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05917210 -
Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda
|
N/A | |
Not yet recruiting |
NCT06017843 -
Impact Evaluation of Use of MATCH AI Predictive Modelling for Identification of Hotspots for TB Active Case Finding
|
N/A | |
Not yet recruiting |
NCT05845112 -
Start Taking Action For TB Diagnosis
|
||
Active, not recruiting |
NCT02715271 -
Study of TB Lesions Obtained in Therapeutical Surgery
|
||
Completed |
NCT02781909 -
Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis
|
Phase 2 |